BD Pen Needles and syringes are used to inject insulin. Always consult your Healthcare Professional regarding treatment of your Diabetes. Always follow the directions for use.

BD AutoShield Duo™ Safety Pen Needle

Supporting you with your injections

Background Image
tabs dropdown arrow


Needlestick injuries from insulin injections represent a major ongoing threat to the safety of healthcare workers and caregivers.1 In one survey, almost 1 in 4 nurses (~24%) had suffered a needlestick injury from giving injections to diabetes patients.1^ In another  study, insulin pens accounted for the most frequent cause of needlestick injuries in nursing homes (40%).  Both the front and back ends of pen needles pose a risk of exposure to bloodborne pathogen virus.3

Features and Benefits

Reduced risk of needlestick injury (NSI)¥

The BD AutoShield Duo™ Safety Pen Needle is designed with automatically-activated protection at both ends of the needle to help prevent needlestick injuries and the transmission of bloodborne diseases during injection and disposal.


~95% of nurses agree that the BD AutoShield Duo™ Safety Pen Needle has a reliable safety mechanism.

Clear safety shield

Clear safety shield on the patient end of the needle covers the pen needle prior to injection, whilst enabling user to visualise the needle.

Visual safety confirmation

Red indicator band on the patient end and orange shield on the non-patient end confirm the activation of the safety mechanisms and protection after use.

Single-handed injection technique

The BD AutoShield Duo™ Safety Pen Needle with a 5mm pen needle does not require a lifted skinfold, thereby minimising the risk of needlestick injury through it.5*†


BD AutoShield Duo™ Safety Pen Needles are compatible with widely-used pen injection devices.6

^400 nurses in 381 different hospitals in the US voluntarily completed a survey.
¥The study was conducted in 45 nursing homes from April 2002 through December 2007.
«A double-blinded survey with 175 nurses from 36 states in the US commissioned in Fall 2021.
*Patients ≤6 years old and very thin adults may require a lifted skinfold
†To minimise the risk of NSI through a lifted skinfold, the use of shorter (4-mm and 5-mm) pen needles without a lifted skinfold is recommended.
¥Compared to non-safety, conventional pen needles


1.    Frid AH, et al. New Insulin Delivery Recommendations. Mayo Clinic Proceedings.
2.    Kiss P, et al. Infect Control Hosp Epidemiol. 2008;29:1192-1194.
3.    Costigliola V, et al. Diab Metab. 2012;38:S9-S14
4.    Data on File. Self-reported Satisfaction and Evaluation of the BD AutoShield Duo™. A survey of acute care and skilled nursing users.
5.    Frid AH, et al. New Insulin Delivery Recommendations. Mayo Clinic Proceedings.
6.    BD Compatibility Confirmation for Pen Needles and Pen Injector Manufacturers. 149-OTH-0004-20, Rev S. February 2021.

embecta, formerly part of BD. BD is the manufacturer of the advertised products.